Business Description
Alector Inc
NAICS : 325412
SIC : 2834
ISIN : US0144421072
Total Employee Number:
103Description
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.98 | |||||
Equity-to-Asset | 0.04 | |||||
Debt-to-Equity | 3.33 | |||||
Debt-to-EBITDA | -0.27 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -5.98 | |||||
Beneish M-Score | -3.09 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -49.9 | |||||
3-Year EBITDA Growth Rate | 3.2 | |||||
3-Year EPS without NRI Growth Rate | 5 | |||||
3-Year FCF Growth Rate | -82.1 | |||||
3-Year Book Growth Rate | -52.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 19.96 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 76.61 | |||||
9-Day RSI | 67.62 | |||||
14-Day RSI | 59.46 | |||||
3-1 Month Momentum % | -19.09 | |||||
6-1 Month Momentum % | 27.45 | |||||
12-1 Month Momentum % | 30 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.25 | |||||
Quick Ratio | 5.25 | |||||
Cash Ratio | 5.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10 | |||||
Shareholder Yield % | 0.68 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -739.7 | |||||
Net Margin % | -680.83 | |||||
EBITDA Margin % | -685.96 | |||||
FCF Margin % | -940.44 | |||||
OCF Margin % | -939.68 | |||||
ROE % | -237 | |||||
ROA % | -38.39 | |||||
ROIC % | -171.49 | |||||
3-Year ROIIC % | 28.86 | |||||
ROC (Joel Greenblatt) % | -479.87 | |||||
ROCE % | -54.55 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 11.68 | |||||
PB Ratio | 21.86 | |||||
Price-to-Tangible-Book | 22.83 | |||||
EV-to-EBIT | -0.41 | |||||
EV-to-EBITDA | -0.44 | |||||
EV-to-Revenue | 3.05 | |||||
EV-to-Forward-Revenue | 22.07 | |||||
EV-to-FCF | -0.32 | |||||
Price-to-GF-Value | 2.82 | |||||
Earnings Yield (Greenblatt) % | -243.9 | |||||
FCF Yield % | -75.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALEC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alector Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 18.417 | ||
| EPS (TTM) ($) | -1.19 | ||
| Beta | 0.8375 | ||
| 3-Year Sharpe Ratio | -0.14 | ||
| 3-Year Sortino Ratio | -0.2 | ||
| Volatility % | 93.78 | ||
| 14-Day RSI | 59.46 | ||
| 14-Day ATR ($) | 0.164662 | ||
| 20-Day SMA ($) | 1.74675 | ||
| 12-1 Month Momentum % | 30 | ||
| 52-Week Range ($) | 1.09 - 3.3999 | ||
| Shares Outstanding (Mil) | 111.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alector Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alector Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 125 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 35 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 34 days | ||
| General meeting for 2026 | 2026-06-17 08:00 | 1.54 (+0.98%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 2.57 (-0.39%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 15:10 | 2.21 (-6.75%) | ||
| Annual report for 2025 | 2026-02-25 | 2.19 (+4.29%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-25 | 2.19 (+4.29%) | ||
| Bank of America CNS Therapeutics Conference | 2025-12-08 14:25 | 1.22 (+0.83%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 1.26 (-4.92%) |
Show
Entries
Alector Inc Frequently Asked Questions
What is Alector Inc(ALEC)'s stock price today?
The current price of ALEC is $2.06. The 52 week high of ALEC is $3.40 and 52 week low is $1.09.
When is next earnings date of Alector Inc(ALEC)?
The next earnings date of Alector Inc(ALEC) is 2026-08-07 Est..
Does Alector Inc(ALEC) pay dividends? If so, how much?
Alector Inc(ALEC) does not pay dividend.
Guru Commentaries on NAS:ALEC
No articles.
Press Release
Articles on Alector Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers